| Field | Specification |
|---|---|
| Target | |
| Alternative names | Beta-hexosaminidase subunit beta;3.2.1.52;Beta-N-acetylhexosaminidase subunit beta;Hexosaminidase subunit B;Cervical cancer proto-oncogene 7 protein;HCC-7;N-acetyl-beta-glucosaminidase subunit beta;Beta-hexosaminidase subunit beta chain B;Beta-hexosaminidase subunit beta chain A;HEXB;HCC7; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human HEXB recombinant protein (Position: K381-M556). Human HEXB shares 75% and 73% amino acid (aa) sequences identity with mouse and rat HEXB, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets beta-hexosaminidase subunit beta (gene HEXB) in human, mouse and rat samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 63.1 kDa, and the supplier reports an observed band at about 63 kDa.
Beta-hexosaminidase subunit beta (HEXB) is a lysosomal enzyme subunit that forms hexosaminidase B (a beta dimer) and, with HEXA, hexosaminidase A. These enzymes remove terminal N-acetylhexosamine residues from glycolipids, glycoproteins and glycosaminoglycans. HEXB mutations cause Sandhoff disease, and it is also studied as a microglial marker.
| Target | Beta-hexosaminidase subunit beta (gene HEXB; UniProt P07686, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 63.1 kDa |
| Observed MW | 63 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
Samples with a confirmed band (WB): human Jurkat cells, human 293T cells, human HeLa cells, rat kidney tissue, rat lung tissue, human HBZY-1 cells, mouse kidney tissue, mouse lung tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 10% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human kidney tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): Caco-2 cells.
Immunogen
Recombinant human HEXB fragment (Lys381–Met556), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 75% and 73%, respectively.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places beta-hexosaminidase subunit beta in the lysosome. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
